Actively Recruiting

Phase 2
Phase 3
Age: 18Years - 75Years
All Genders
NCT07499700

A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis

Led by Bio-Thera Solutions · Updated on 2026-04-03

192

Participants Needed

1

Research Sites

265 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a phase II/III multicenter, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of BAT4406F injection in patients with Minimal Change Disease/Focal Segmental Glomerulosclerosis

CONDITIONS

Official Title

A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Clinically diagnosed with nephrotic syndrome, confirmed by kidney biopsy showing Minimal Change Disease within 7 years or Focal Segmental Glomerulosclerosis within 10 years before screening
  • Responsive to corticosteroid therapy
  • Achieved complete remission after corticosteroid treatment within 8 weeks before baseline
Not Eligible

You will not qualify if you...

  • Secondary nephrotic syndrome
  • Known genetic defects causing nephrotic syndrome or family history of nephrotic syndrome
  • Received B-cell depletion or modifying therapy within 6 months before baseline
  • Allergy to monoclonal antibodies or predisposition to allergies
  • Used immunosuppressants within 60 days before baseline
  • Received immunoglobulin within 90 days or immunomodulators like thymosin within 4 weeks before baseline
  • Participated in another investigational drug trial within 90 days before baseline or plans to during this study
  • Significant abnormal liver or kidney function
  • Positive for hepatitis B surface antigen, hepatitis C antibodies, syphilis antibodies, HIV infection or antibodies

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Peking University First Hospital

Beijing, Beijing Municipality, China

Actively Recruiting

Loading map...

Research Team

M

mei Xiao An

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here